Update on tumor metabolism and patterns of response to immunotherapy

Research output: Contribution to journalArticlepeer-review

Abstract

Immune checkpoint inhibitors (ICI) represent a cornerstone in cancer treatment. However, the peculiarity of immune response, determining distinctive response patterns and toxicity events, challenges the conventional response criteria. Therefore, the effective tumor response and the real clinical benefit cannot be demonstrated adequately. In this context, recent studies using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]) positron emission tomography/computed tomography (PET/CT) have shown promising results for therapeutic monitoring during ICI, although further research is needed to confirm its potentials. In this review, we focus on the latest evidences and challenges regarding the assessment of morphological and metabolic parameters in the evaluation of ICI therapy. We will also discuss a wide range of emerging imaging-based biomarkers for anti-checkpoint therapy as well as their challenges in the clinical practice.

Original languageEnglish
Pages (from-to)175-185
Number of pages11
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume64
Issue number2
DOIs
Publication statusPublished - Jun 2020

Fingerprint Dive into the research topics of 'Update on tumor metabolism and patterns of response to immunotherapy'. Together they form a unique fingerprint.

Cite this